We are live on ! Find out more
HVC

Healthcare Value Capital Portfolio holdings

AUM $50.7M
1-Year Est. Return 24.72%
This Fund
S&P 500
This Quarter Est. Return
+8.4%
1 Year Est. Return
+24.72%
3 Year Est. Return
+18.99%
5 Year Est. Return
+98.49%
10 Year Est. Return
–
AUM
$91.8M
AUM Growth
+$37M
Cap. Flow
+$13.4M
Cap. Flow %
14.65%
Top 10 Hldgs %
67.6%
Holding
39
New
12
Increased
4
Reduced
5
Closed
3

Top Buys

Rank Stock Value
1
TWM icon
ProShares UltraShort Russell2000
TWM
+$3.86M
2
BIS icon
ProShares UltraShort NASDAQ Biotechnology
BIS
+$3.83M
3
AGN
Allergan plc
AGN
+$2.85M
4
QLTI
QLT Inc
QLTI
+$2.32M
5
ADYX
Adynxx Inc
ADYX
+$1.06M

Top Sells

Rank Stock Value
1
AMRI
Albany Molecular Research Inc
AMRI
+$951K
2
RIGL icon
Rigel Pharmaceuticals
RIGL
+$685K
3
SRNE
Sorrento Therapeutics, Inc.
SRNE
+$642K
4
CPRX
Catalyst Pharmaceutical
CPRX
+$149K
5
IMNN icon
Imunon
IMNN
+$55.7K

Sector Composition

Rank Sector Weight
1 Healthcare 61.46%
2 Miscellaneous 38.54%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AEGR
26
DELISTED
Aegerion Pharmaceuticals
AEGR
$654K 0.71%
+25,000
New +$636K
QLTI
27
CALL
DELISTED
QLT Inc
QLTI
$587K 0.64%
150,000
– –
RIGL icon
28
Rigel Pharmaceuticals
RIGL
$875M
$536K 0.58%
15,000
-25,000
-63% -$685K
ALIM
29
DELISTED
Alimera Sciences
ALIM
$501K 0.55%
6,667
– –
VIRX
30
CALL
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
$490K 0.53%
+952
New +$480K
VIRX
31
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
$490K 0.53%
952
– –
AMRN
32
CALL
Amarin Corp
AMRN
$297M
$468K 0.51%
10,000
-15,000
-60% -$458K
AMRN
33
Amarin Corp
AMRN
$297M
$468K 0.51%
+10,000
New +$305K
STML
34
DELISTED
Stemline Therapeutics, Inc.
STML
$362K 0.39%
25,000
+8,536
+52% +$131K
ALIM
35
CALL
DELISTED
Alimera Sciences
ALIM
$251K 0.27%
3,333
– –
IMNN icon
36
Imunon
IMNN
$8.98M
$214K 0.23%
29
-8
-22% -$55.7K
CPRX
37
DELISTED
Catalyst Pharmaceutical
CPRX
– –
-50,000
Closed -$149K
CEMP
38
CALL
DELISTED
Cempra, Inc.
CEMP
– –
-40,000
Closed -$940K
POZN
39
CALL
DELISTED
POZEN INC
POZN
– –
-50,000
Closed -$400K
1
2

Similar funds

C
Castlelake Minneapolis, Minnesota $48.5M AUM 87.77% 1-Year Est. Return
CC
Cedar Capital Barrington, Illinois $54.9M AUM 33.3% 1-Year Est. Return
FCOI
FirstMark Capital OF II New York $44.1M AUM 18.15% 1-Year Est. Return
FCOI
FirstMark Capital OF I New York $43.1M AUM 6.31% 1-Year Est. Return
BI
BCBSM Inc Eagan, Minnesota $42.4M AUM 0.4% 1-Year Est. Return
KC
Kelso & Company New York $42.3M AUM
SCIM
Spring Creek Investment Management Philadelphia, Pennsylvania $42.3M AUM 31.86% 1-Year Est. Return
MCP
Moab Capital Partners Southampton, New York $41M AUM 33.21% 1-Year Est. Return

Healthcare Value Capital's Q1 2015 Portfolio in Review

As of Q1 2015, Healthcare Value Capital held 39 positions worth $91.8M, up 68% from $54.7M the previous quarter. Its ten largest holdings account for 68% of the portfolio.

Healthcare Value Capital deployed $13.4M of net new capital in Q1 2015, opening 12 new positions and adding to 4 existing holdings. Its largest new stake was ProShares UltraShort NASDAQ Biotechnology: 12,500 shares worth $3.45M.

By sector, the portfolio is most concentrated in Healthcare at 61% of assets, down from 83% a quarter earlier, followed by Miscellaneous.

On the sell side, the largest reduction was Albany Molecular Research Inc, an estimated $951K trimmed.

  • Healthcare Value Capital's largest Q1 2015 buy was ProShares UltraShort NASDAQ Biotechnology: 12,500 shares worth $3.45M.
  • Healthcare Value Capital added most to ProShares UltraShort Russell2000 in Q1 2015, an estimated $3.86M increase.
  • Healthcare Value Capital's biggest Q1 2015 reduction was Albany Molecular Research Inc, cutting an estimated $951K.
  • Healthcare Value Capital fully exited Catalyst Pharmaceutical in Q1 2015, selling an estimated $149K.
  • Healthcare Value Capital's ten largest holdings make up 68% of its $91.8M portfolio in Q1 2015.
  • Healthcare Value Capital opened 12 new positions and closed 3 in Q1 2015.
  • Healthcare Value Capital's portfolio value rose 68% quarter-over-quarter to $91.8M.

Based on Healthcare Value Capital's 13F filing for Q1 2015, filed 14 May 2015.